tiprankstipranks
Ultragenyx Pharmaceutical (CH:UP0)
:UP0
Switzerland Market
UP0
Ultragenyx Pharmaceutical
RESEARCH TOOLSreports

Ultragenyx Pharmaceutical (UP0) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

UP0 Analyst Ratings

Strong Buy
18Ratings
Strong Buy
16 Buy
2 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Ultragenyx
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UP0 Stock 12 Month Forecast

Average Price Target

―
Based on 18 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is CHF44.65 with a high forecast of CHF82.74 and a low forecast of CHF22.49. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF82.74Average Price TargetCHF44.65Lowest Price TargetCHF22.49
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on CH:UP0
Anupam Rama
J.P. Morgan
J.P. Morgan
CHF60.25→CHF64.26
Buy
―
Assigned
08/25/26
J.P. Morgan Issues a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Jefferies Analyst forecast on CH:UP0
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF61.85
Buy
―
Reiterated
08/21/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Jefferies
H.C. Wainwright Analyst forecast on CH:UP0
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF40.17
Buy
―
Reiterated
08/21/26
Ultragenyx: FDA-Backed Gene Therapy Momentum and Late-Stage Pipeline Support Reiterated Buy Rating and Unchanged $50 Price Target
Morgan Stanley Analyst forecast on CH:UP0
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF53.82→CHF59.44
Buy
―
Assigned
08/21/26
Analysts' Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)
Wedbush Analyst forecast on CH:UP0
Unknown Analyst
Wedbush
Not Ranked
Wedbush
CHF24.1
Hold
―
Reiterated
08/20/26
Wedbush Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)
William Blair Analyst forecast on CH:UP0
Sami Corwin
William Blair
William Blair
―
Buy
―
Initiated
08/20/26
Ultragenyx: Strengthening Gene Therapy Franchise and Upcoming Clinical Catalysts Support Buy Rating
Canaccord Genuity Analyst forecast on CH:UP0
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF65.07→CHF66.67
Buy
―
Reiterated
08/20/26
Ultragenyx price target raised to $83 from $81 at CanaccordUltragenyx price target raised to $83 from $81 at Canaccord
Citi Analyst forecast on CH:UP0
Yigal Nochomovitz
Citi
Citi
CHF36.15→CHF46.59
Buy
―
Reiterated
08/20/26
Ultragenyx price target raised to $58 from $45 at CitiUltragenyx price target raised to $58 from $45 at Citi
Goldman Sachs Analyst forecast on CH:UP0
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF21.69→CHF22.49
Hold
―
Reiterated
08/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), Ascendis Pharma (NASDAQ: ASND) and Aurinia Pharmaceuticals (NASDAQ: AUPH)
Bank of America Securities Analyst forecast on CH:UP0
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF36.95→CHF38.56
Buy
―
Reiterated
08/20/26
Ultragenyx price target raised to $48 from $46 at BofAUltragenyx price target raised to $48 from $46 at BofA
Wells Fargo Analyst forecast on CH:UP0
Benjamin Burnett
Wells Fargo
Wells Fargo
CHF36.15→CHF36.95
Buy
―
Assigned
08/20/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Wells Fargo
TD Cowen Analyst forecast on CH:UP0
Yaron Werber
TD Cowen
TD Cowen
CHF39.36
Buy
―
Reiterated
08/19/26
Ultragenyx Pharmaceutical (RARE) Receives a Rating Update from a Top Analyst
Cantor Fitzgerald Analyst forecast on CH:UP0
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF77.12→CHF82.74
Buy
―
Reiterated
08/19/26
Cantor Fitzgerald Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Piper Sandler Analyst forecast on CH:UP0
Allison Bratzel
Piper Sandler
Piper Sandler
CHF54.62
Buy
―
Reiterated
08/17/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Piper Sandler
Evercore ISI Analyst forecast on CH:UP0
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
CHF26.51
Buy
―
Reiterated
08/10/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on CH:UP0
Anupam Rama
J.P. Morgan
J.P. Morgan
CHF60.25→CHF64.26
Buy
―
Assigned
08/25/26
J.P. Morgan Issues a Buy Rating on Ultragenyx Pharmaceutical (RARE)
Jefferies Analyst forecast on CH:UP0
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF61.85
Buy
―
Reiterated
08/21/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Jefferies
H.C. Wainwright Analyst forecast on CH:UP0
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF40.17
Buy
―
Reiterated
08/21/26
Ultragenyx: FDA-Backed Gene Therapy Momentum and Late-Stage Pipeline Support Reiterated Buy Rating and Unchanged $50 Price Target
Morgan Stanley Analyst forecast on CH:UP0
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF53.82→CHF59.44
Buy
―
Assigned
08/21/26
Analysts' Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)
Wedbush Analyst forecast on CH:UP0
Unknown Analyst
Wedbush
Not Ranked
Wedbush
CHF24.1
Hold
―
Reiterated
08/20/26
Wedbush Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)
William Blair Analyst forecast on CH:UP0
Sami Corwin
William Blair
William Blair
―
Buy
―
Initiated
08/20/26
Ultragenyx: Strengthening Gene Therapy Franchise and Upcoming Clinical Catalysts Support Buy Rating
Canaccord Genuity Analyst forecast on CH:UP0
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF65.07→CHF66.67
Buy
―
Reiterated
08/20/26
Ultragenyx price target raised to $83 from $81 at CanaccordUltragenyx price target raised to $83 from $81 at Canaccord
Citi Analyst forecast on CH:UP0
Yigal Nochomovitz
Citi
Citi
CHF36.15→CHF46.59
Buy
―
Reiterated
08/20/26
Ultragenyx price target raised to $58 from $45 at CitiUltragenyx price target raised to $58 from $45 at Citi
Goldman Sachs Analyst forecast on CH:UP0
Salveen Richter
Goldman Sachs
Goldman Sachs
CHF21.69→CHF22.49
Hold
―
Reiterated
08/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), Ascendis Pharma (NASDAQ: ASND) and Aurinia Pharmaceuticals (NASDAQ: AUPH)
Bank of America Securities Analyst forecast on CH:UP0
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
CHF36.95→CHF38.56
Buy
―
Reiterated
08/20/26
Ultragenyx price target raised to $48 from $46 at BofAUltragenyx price target raised to $48 from $46 at BofA
Wells Fargo Analyst forecast on CH:UP0
Benjamin Burnett
Wells Fargo
Wells Fargo
CHF36.15→CHF36.95
Buy
―
Assigned
08/20/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Wells Fargo
TD Cowen Analyst forecast on CH:UP0
Yaron Werber
TD Cowen
TD Cowen
CHF39.36
Buy
―
Reiterated
08/19/26
Ultragenyx Pharmaceutical (RARE) Receives a Rating Update from a Top Analyst
Cantor Fitzgerald Analyst forecast on CH:UP0
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF77.12→CHF82.74
Buy
―
Reiterated
08/19/26
Cantor Fitzgerald Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Piper Sandler Analyst forecast on CH:UP0
Allison Bratzel
Piper Sandler
Piper Sandler
CHF54.62
Buy
―
Reiterated
08/17/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Piper Sandler
Evercore ISI Analyst forecast on CH:UP0
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
CHF26.51
Buy
―
Reiterated
08/10/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

3 Months
Whitney IjemCanaccord Genuity
Success Rate
11/17 ratings generated profit
65%
Average Return
+6.41%
Copying Whitney Ijem's trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +6.41% per trade.
1 Year
Yigal NochomovitzCiti
Success Rate
10/20 ratings generated profit
50%
Average Return
-0.18%
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -0.18% per trade.
2 Years
Yigal NochomovitzCiti
Success Rate
7/20 ratings generated profit
35%
Average Return
-12.75%
Copying Yigal Nochomovitz's trades and holding each position for 2 Years would result in 35.00% of your transactions generating a profit, with an average return of -12.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UP0 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
20
18
16
14
23
Buy
6
3
3
4
7
Hold
2
2
1
4
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
23
20
22
36
In the current month, UP0 has received 30 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. UP0 average Analyst price target in the past 3 months is 44.65.
Each month's total comprises the sum of three months' worth of ratings.

UP0 Financial Forecast

UP0 Earnings Forecast

Next quarter’s earnings estimate for UP0 is -CHF0.69 with a range of -CHF1.04 to CHF0.60. The previous quarter’s EPS was -CHF0.72. UP0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for UP0 is -CHF0.69 with a range of -CHF1.04 to CHF0.60. The previous quarter’s EPS was -CHF0.72. UP0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.

UP0 Sales Forecast

Next quarter’s sales forecast for UP0 is CHF147.85M with a range of CHF134.96M to CHF163.17M. The previous quarter’s sales results were CHF171.91M. UP0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.
Next quarter’s sales forecast for UP0 is CHF147.85M with a range of CHF134.96M to CHF163.17M. The previous quarter’s sales results were CHF171.91M. UP0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.

UP0 Stock Forecast FAQ

What is CH:UP0’s average 12-month price target, according to analysts?
Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 44.65.
    What is CH:UP0’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:UP0, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Ultragenyx Pharmaceutical a Buy, Sell or Hold?
        Ultragenyx Pharmaceutical has a consensus rating of Strong Buy, which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.
          What is Ultragenyx Pharmaceutical’s share price target?
          The average share price target for Ultragenyx Pharmaceutical is 44.65. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF82.74 ,and the lowest forecast is CHF22.49. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Ultragenyx Pharmaceutical?
            Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
              How can I buy shares of Ultragenyx Pharmaceutical?
              To buy shares of CH:UP0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.